Recent advances in therapeutic strategies for triple-negative breast cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent advances in therapeutic strategies for triple-negative breast cancer
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 15, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-29
DOI
10.1186/s13045-022-01341-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial
- (2022) Valentina Boni et al. CLINICAL CANCER RESEARCH
- A First-in-Human, Phase 1, Multicenter, Open-label, Dose-Escalation Study of PCA062, an Antibody-Drug Conjugate Targeting P-Cadherin, in Patients with Solid Tumors
- (2022) Matteo Duca et al. MOLECULAR CANCER THERAPEUTICS
- Structural study of ponatinib in inhibiting SRC kinase
- (2022) Ming Guo et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
- (2022) Chiara Corti et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment
- (2022) Chaoyu Zhang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer
- (2022) Jong-Ho Cha et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4
- (2022) Min Shao et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
- (2022) Ji Young Kim et al. ONCOGENE
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
- (2022) Lisa A. Carey et al. npj Breast Cancer
- Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
- (2021) Kartik Anand et al. Scientific Reports
- Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment
- (2021) Maojun Zhou et al. Aging-US
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer
- (2021) Filipa Lynce et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- FGFR-TKI resistance in cancer: current status and perspectives
- (2021) Sitong Yue et al. Journal of Hematology & Oncology
- Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
- (2021) Eric P Winer et al. LANCET ONCOLOGY
- Antibody‒drug conjugates: Recent advances in linker chemistry
- (2021) Zheng Su et al. Acta Pharmaceutica Sinica B
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer
- (2021) Michel Demeule et al. CANCER SCIENCE
- First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
- (2021) Michael L. Maitland et al. CLINICAL CANCER RESEARCH
- Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
- (2021) Linda T. Vahdat et al. npj Breast Cancer
- Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
- (2020) F. Mosele et al. ANNALS OF ONCOLOGY
- Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis
- (2020) Meng Xu et al. Clinical Breast Cancer
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody–drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer
- (2020) Hang-Ping Yao et al. DRUG DISCOVERY TODAY
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
- (2020) Luis Paz-Ares et al. Journal of Thoracic Oncology
- An antibody drug conjugate targeting MUC1 associated carbohydrate CA6, shows promising anti-tumor activities
- (2020) Celine Nicolazzi et al. MOLECULAR CANCER THERAPEUTICS
- Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
- (2020) Jennifer Y. Ge et al. Nature Communications
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
- (2020) Jieqiong Liu et al. Journal for ImmunoTherapy of Cancer
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) Changhoon Yoo et al. Journal for ImmunoTherapy of Cancer
- Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
- (2020) Jin Sun Lee et al. Cancers
- Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial
- (2020) Yi-Zhou Jiang et al. CELL RESEARCH
- Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer
- (2020) Ke-Da Yu et al. JAMA Oncology
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
- (2020) Byoung Chul Cho et al. Journal for ImmunoTherapy of Cancer
- Retinoblastoma protein expression and its predictors in triple-negative breast cancer
- (2020) Jaymin M. Patel et al. npj Breast Cancer
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
- (2020) Heng Wei et al. Frontiers in Immunology
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer
- (2020) Yuan Yuan et al. ONCOLOGIST
- Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite
- (2019) Wei-Siang Liao et al. Acta Biomaterialia
- Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer
- (2019) Takuro Yamamoto et al. BREAST CANCER RESEARCH AND TREATMENT
- Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
- (2019) Ana C. Garrido-Castro et al. Cancer Discovery
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
- (2019) Tina Gruosso et al. JOURNAL OF CLINICAL INVESTIGATION
- Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer
- (2019) Nicole M. Kettner et al. CLINICAL CANCER RESEARCH
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
- (2019) Yi-Zhou Jiang et al. CANCER CELL
- Recent advances in triple negative breast cancer: the immunotherapy era
- (2019) Antonio Marra et al. BMC Medicine
- FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer
- (2019) M Oliveira et al. ANNALS OF ONCOLOGY
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
- (2019) Wei Wen et al. Cells
- RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype
- (2019) Demin Cai et al. Nature Communications
- CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
- (2019) Lei Nie et al. Nature Communications
- GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
- (2019) Christian M. Seitz et al. OncoImmunology
- EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
- (2019) Yan Liu et al. Aging-US
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
- (2018) Peter A. Fasching et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
- (2018) Sonia Pernas et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling
- (2018) Pernilla Roswall et al. NATURE MEDICINE
- A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
- (2018) Xiujuan Wu et al. Nature Communications
- Peptide density targets and impedes triple negative breast cancer metastasis
- (2018) Daxing Liu et al. Nature Communications
- LY2874455 potently inhibits FGFR gatekeeper mutant and overcomes mutation-based resistance
- (2018) Daichao Wu et al. CHEMICAL COMMUNICATIONS
- Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials
- (2018) Hope S. Rugo et al. Clinical Breast Cancer
- Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial
- (2018) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer
- (2018) Wenyu Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors
- (2018) Pedro Miguel Lacal et al. PHARMACOLOGICAL RESEARCH
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Sacituzumab govitecan activity in advanced breast cancer
- (2017) Talha Khan Burki LANCET ONCOLOGY
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
- (2017) Delphine Merino et al. Science Translational Medicine
- A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions
- (2017) Marc Damelin et al. Science Translational Medicine
- Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
- (2017) Emma Nolan et al. Science Translational Medicine
- Heat Shock Proteins and Cancer
- (2017) Jianming Wu et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer
- (2017) Eric Hahnen et al. JAMA Oncology
- A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2− advanced breast cancer (BELLE-4)
- (2016) M. Martín et al. ANNALS OF ONCOLOGY
- Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
- (2016) U.A. Matulonis et al. ANNALS OF ONCOLOGY
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
- (2016) Pau Castel et al. CANCER CELL
- Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients
- (2016) Winston W. Tan et al. Clinical Breast Cancer
- Cyclin-dependent kinase pathways as targets for womenʼs cancer treatment
- (2016) Gottfried E. Konecny CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
- (2016) N.C. Synnott et al. INTERNATIONAL JOURNAL OF CANCER
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- (2016) Hope S. Rugo et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
- (2016) A. Pearson et al. Cancer Discovery
- Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma
- (2016) Uddalak Bharadwaj et al. Oncotarget
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
- (2015) Fabrice André et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
- (2015) F Caiazza et al. BRITISH JOURNAL OF CANCER
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
- (2015) Herbert I. Hurwitz et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
- (2015) Khanh Do et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
- (2015) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
- (2015) Xi-Chun Hu et al. LANCET ONCOLOGY
- Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer
- (2015) Katherine M. Lewis et al. LUNG CANCER
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Bevacizumab in neoadjuvant chemotherapy increases the pathological complete response rate in patients with triple-negative breast cancer
- (2014) Mary Kay Barton CA-A CANCER JOURNAL FOR CLINICIANS
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
- (2014) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
- (2014) Johanna Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario
- (2014) M. Bonotto et al. ONCOLOGIST
- Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy
- (2013) Minhao Fan et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
- (2013) Neil E. Bhola et al. JOURNAL OF CLINICAL INVESTIGATION
- IAP proteins as targets for drug development in oncology
- (2013) Laurence Dubrez et al. OncoTargets and Therapy
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells
- (2012) Kosuke Yamamoto et al. BIOCHEMICAL JOURNAL
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- A Gene Signature for Predicting Outcome in Patients with Basal-like Breast Cancer
- (2012) Robin M. Hallett et al. Scientific Reports
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
- (2011) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors
- (2011) Lauren L.C. Marotta et al. JOURNAL OF CLINICAL INVESTIGATION
- A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment
- (2011) Qian Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer
- (2010) Lyndsay V. Rhodes et al. CANCER RESEARCH
- Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
- (2010) H. Harrison et al. CANCER RESEARCH
- Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
- (2010) Andrew J. Woodhead et al. JOURNAL OF MEDICINAL CHEMISTRY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells
- (2010) X T Zhang et al. ONCOGENE
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
- (2010) N Turner et al. ONCOGENE
- Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
- (2009) Emmanuelle Charafe-Jauffret et al. CANCER RESEARCH
- A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer
- (2009) Theresa A. DiMeo et al. CANCER RESEARCH
- Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
- (2009) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
- (2008) Sendurai A. Mani et al. CELL
- TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
- (2008) David Padua et al. CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now